3B Blackbio Dx profit and loss

Latest FY25
Revenue
₹90.5cr+28.0% on FY24
EBITDA
₹49.9cr+42.0% on FY24
₹ crore except per share
Tap a line for its trendFY25Mar 2025FY24Mar 2024
90.570.7
15.012.3
10683.0
Expenses
6.25.1
0.10.1
0.90.9
10.110.3
49.935.1
49.034.2
Profit
63.946.4
14.810.8
1.51.4
16.312.2
47.634.2
47.634.2
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

3BBLACKBIO₹1,359.20

3B Blackbio Dx Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersHEALTHXSURAKSHAKRSNAANEPHROPLUS
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
Revenue from Operations70.790.5
Other Income12.315.0
Total Income83.0105.6
Expenses
+ Employee Benefit Expense5.16.2
+ Finance Costs0.10.1
+ Depreciation & Amortisation0.90.9
+ Other Expenses10.310.1
EBITDA35.149.9
EBIT34.249.0
Profit
Pretax Income46.463.9
+ Current Tax10.814.8
+ Deferred Tax1.41.5
Tax Expense12.216.3
Net Income34.247.6
Total Comprehensive Income34.247.6
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.